TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06159673: ACP-204 in Adults With Alzheimer's Disease Psychosis

Sponsor: ACADIA Pharmaceuticals Inc. · Phase: PHASE2/PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 1074 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,644,872

Rescue Site Savings

+$2,414,136

Unlock Full NCT06159673 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06159673 Rescue Dossier →